Clinical Trial ProgressBicara's drug combo maintains mOS above 11 months in HPV negative patients, which is a clear path to approval.
Investment PotentialThe analyst reiterates a Buy rating for Bicara Therapeutics Inc., suggesting confidence in the company's future performance and potential stock appreciation.
Regulatory MilestonesThe FDA has granted Ficerafusp Alfa Breakthrough Therapy Designation for the treatment of certain types of head and neck cancer, highlighting its potential effectiveness.